Overview

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Status:
Not yet recruiting

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of camrelizumab in combination with apatinib and chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC).

Phase:

Phase 2

Details

Lead Sponsor:

West China Hospital

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Apatinib
Cyclophosphamide
Epirubicin
Paclitaxel